Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.49 |
| ▸ | GRM5 | P41594 | 4/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6911471 | 0.82 | TRPM8 (0.48) | TRPM8TRPA1EPHX1KCNA5TRPV1 | |
| SCHEMBL11855364 | 0.81 | TRPM8 (0.47) | TRPM8TRPA1EPHX1KCNA5TRPV1 | |
| SCHEMBL2123054 | 0.81 | EPHX1 (0.49) | TRPM8TRPA1EPHX1KCNA5TRPV1 | |
| SCHEMBL18626368 | 0.78 | TRPM8 (0.52) | TRPM8TRPA1EPHX1KCNA5TRPV1 | |
| Menthol SCHEMBL6238698 | 0.76 | TRPM8 (0.78) | TRPM8TRPA1EPHX1KCNA5TRPV1 | |
| Levomenthol SCHEMBL28048330 | 0.76 | TRPM8 (0.78) | TRPM8TRPA1EPHX1KCNA5TRPV1 | |
| SCHEMBL11406214 | 0.75 | GRM5 (0.31) | TRPM8TRPA1GRM5GRM1 | |
| SCHEMBL19067387 | 0.74 | TRPM8 (0.48) | TRPM8TRPA1EPHX1KCNA5TRPV1 | |
| SCHEMBL9514707 | 0.74 | TRPM8 (0.41) | TRPM8TRPA1EPHX1KCNA5TRPV1 | |
| SCHEMBL6242091 | 0.73 | TRPM8 (0.52) | TRPM8TRPA1EPHX1KCNA5TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2196460-B1 | SULFONIC ACID SALT COMPOUND OF 4-CARBAMOYL-5-HYDROXY-IMIDAZOLE DERIVATIVE | FUJIFILM CORP (JP) | 2016-02-17 | — | — | EP | claimed |
| US-20100210855-A1 | SULFONIC ACID SALT COMPOUND OF 4-CARBAMOYL-5-HYDROXY-IMIDAZOLE DERIVATIVE | FUJIFILM CORPORATION (JP) | 2010-08-19 | — | — | US | claimed |
| EP-2196460-A1 | SULFONIC ACID SALT COMPOUND OF 4-CARBAMOYL-5-HYDROXY-IMIDAZOLE DERIVATIVE | MBR Co., Ltd. (JP) | 2010-06-16 | — | — | EP | claimed |
| US-12569481-B2 | Methods of treatment for gastrointestinal motility disorders | VANDERBILT UNIVERSITY (US) | 2026-03-10 | — | — | US | disclosed |
| US-12472158-B2 | Methods of treating trigeminal nerve pain | VANDERBILT UNIVERSITY (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250154219-A1 | PEPTIDE ANALOGS | ADEPTHERA LLC | 2025-05-15 | — | — | US | disclosed |
| US-12161761-B2 | Extended release multiparticulates of ranolazine | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2024-12-10 | — | — | US | disclosed |
| WO-2024249843-A2 | GUANFACINE FOR FATIGUE DISORDERS | VANDERBILT UNIVERSITY (US) | 2024-12-05 | — | — | WO | disclosed |
| US-12110318-B2 | Peptide analogs | ADEPTHERA LLC (US) | 2024-10-08 | — | — | US | disclosed |
| US-12103951-B2 | Use of CGRP receptor antagonists in neuroprotection and neurological disorders | SOARES CHRISTOPHER JOSEPH (US) | 2024-10-01 | — | — | US | disclosed |
| EP-4316595-A2 | USE OF CGRP RECEPTOR ANTAGONISTS IN TREATING GLAUCOMA | Soares, Christopher, J. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20110152377-A1 | EXTERNAL PREPARATION COMPRISING FATTY ACID SALT OR BENZOIC ACID SALT OF BASIC PHARMACOLOGICALLY ACTIVE COMPONENT, AND METHOD FOR PRODUCTION THEREOF | MEDRX CO., LTD. (JP) | 2011-06-23 | — | — | US | disclosed |
| EP-2311498-A1 | EXTERNAL PREPARATION COMPRISING FATTY ACID SALT OR BENZOIC ACID SALT OF BASIC PHARMACOLOGICALLY ACTIVE COMPONENT, AND METHOD FOR PRODUCTION THEREOF | Medrx Co., Ltd. (JP) | 2011-04-20 | — | — | EP | disclosed |
| CN-101287749-A | Peptides and compounds that bind to a receptor | ORTHO MCNEIL PHARM INC (US) | 2008-10-15 | — | — | CN | disclosed |
| CN-101273987-A | Use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases | NOVARTIS AG (CH) | 2008-10-01 | — | — | CN | disclosed |
| CN-100402026-C | Use of substituted cyanopyrrolidines and combination preparations containing them for the treatment of hyperlipidemia and related diseases | NOVARTIS AG (CH) | 2008-07-16 | — | — | CN | disclosed |
| CN-1658867-A | Use of substituted cyanopyrrolidines and combination preparations containing them for the treatment of hyperlipidemia and related diseases | NOVARTIS AG (CH) | 2005-08-24 | — | — | CN | disclosed |
| CN-1426467-A | Thrombopoietin receptor modulating peptide | PLIVA PHARM & CHEM WORKS (HR) | 2003-06-25 | — | — | CN | disclosed |
| US-4606851-A | Method for improving water solubility of surfactants using terpene sulfonate hydrotropes | LEVER BROTHERS COMPANY (US) | 1986-08-19 | — | — | US | disclosed |
| US-4528144-A | Terpene sulfonate hydrotropes | LEVER BROTHERS COMPANY (US) | 1985-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569481-B2 | Methods of treatment for gastrointestinal motility disorders | SLC10A2, HCN4, SCN2B | TRPM8 100/4885TRPA1 35/4885EPHX1 3086/4885 |
| US-12110318-B2 | Peptide analogs | RAMP1, RAMP3, RAMP2 | TRPM8 153/4885TRPA1 325/4885EPHX1 3409/4885 |
| US-20250154219-A1 | PEPTIDE ANALOGS | RAMP1, RAMP2, RAMP3 | TRPM8 155/4885TRPA1 279/4885EPHX1 3271/4885 |
| US-20100210855-A1 | SULFONIC ACID SALT COMPOUND OF 4-CARBAMOYL-5-HYDROXY-IMIDAZOLE DERIVATIVE | CA12, CA14, CA2 | TRPM8 116/4885TRPA1 2007/4885EPHX1 3627/4885 |
| US-12472158-B2 | Methods of treating trigeminal nerve pain | NGF, ADRA2C, OPRL1 | TRPM8 1078/4885TRPA1 216/4885EPHX1 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.